Zhitong Financial APP, Renhe Pharmaceutical (000650.SZ) announced that Jiangxi Pharmaceutical Co., Ltd., a subsidiary of the company, recently received a "Drug Registration Certificate" on Atto vastatin calcium tablets (specification 20mg) approved and issued by the State Drug Administration. As of the announcement date, the cumulative R & D cost of Atto vastatin calcium tablets is about 16.5 million yuan (unaudited).

The company Atto vastatin calcium tablets has obtained the "Drug Registration Certificate" of the State Drug Administration, which indicates that the company is qualified to produce and sell the drug in the domestic market, further enriching the company's product line and helping to enhance the market competitiveness of the company's products.